Navigation Links
BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
Date:9/30/2009

NOVATO, Calif., Sept. 30 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, October 28, at 5:00 p.m. ET to discuss third quarter 2009 financial results.

    U.S. / Canada Dial-in Number:  800.299.6183
    International Dial-in Number:  617.801.9713
    Participant Code: 51404008
    Replay Dial-in Number: 888.286.8010
    Replay International Dial-in Number: 617.801.6888
    Replay Code: 51416825

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development fo
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMarin to Present at the Morgan Stanley Healthcare Conference
2. BioMarin to Present at the Baird Healthcare Conference
3. BioMarin to Present at the Jefferies Healthcare Conference
4. BioMarin to Present at the Goldman Sachs Healthcare Conference
5. BioMarin to Present at the Deutsche Bank Health Care Conference
6. BioMarin to Present at the Baird Growth Stock Conference
7. BioMarin Announces First Quarter 2009 Financial Results
8. BioMarin to Host First Quarter 2009 Financial Results Conference Call and Webcast on Thursday, April 30 at 5:00 p.m. ET (23:00 CET)
9. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
10. BioMarin to Present at the 4th Annual Citi Biotech Day
11. BioMarins Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... CAMBRIDGE, Mass. , May 22, 2013  Moderna ... revolutionary new treatment modality to enable the in ... John Reynders will join Moderna ... Reynders is a proven leader in ... phases of drug development, from discovery to translation, clinical ...
(Date:5/21/2013)... May 21, 2013  The Lindsley F. Kimball Research Institute ... is a Grand Challenges Explorations winner, an initiative ... Dr. Sara Lustigman , Head of the ... and development research project, titled Innovative 3-D in ... are needed to screen drugs to help eliminate onchocerciasis (river ...
(Date:5/21/2013)... a new study led by George Washington University ... nucleation of ice in small droplets is strongly ... at the nanoscale. The formation of ice at ... question whose answer also has important implications for ... crystallization of ice from supercooled water is generally ...
(Date:5/21/2013)... Branchburg, NJ (PRWEB) May 21, 2013 ... enhancement industry, has appointed Dale Braddy to Southeastern USA ... proactively bolster its sales muscle in the Southeast. ... a food ingredient brokerage and supplier to food processors ... past 13 years in the food industry and has ...
Breaking Biology Technology:Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 3Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2
... Augments Senior Management Team with Recent Strategic Hires ... ... May 14 Triple-S,Management Corporation (NYSE: GTS ) today announced that ... for the Children,s Oncology Group and,the Dana Farber Acute Lymphoblastic Leukemia Consortium, ...
... Executive Chairman Set Sights on Expanding,Therapeutic Horizons of ... BOSTON, SAN DIEGO, SAN FRANCISCO and SEATTLE, May ... joined Fate Therapeutics as,president and CEO and executive ... internationally recognized stem cell scientists,clinicians and investors dedicated ...
... 14 Campbell Alliance,the leading management consulting firm ... that Gary Tyson, Senior Vice,President of the firm,s ... the global rollout of electronic data capture (EDC),systems ... will be,held on May 28-29, 2008, at the ...
Cached Biology Technology:Triple-S Management Corporation Appoints New Non-Executive Chairman to Board; Adds New Director 2Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 2Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 3Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 4Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 5Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 6Campbell Alliance Clinical Development Practice to Present Session on Global EDC Rollout at Clinical Trials Congress, Europe 2Campbell Alliance Clinical Development Practice to Present Session on Global EDC Rollout at Clinical Trials Congress, Europe 3
(Date:5/21/2013)... world,s largest scientific society, invites news media coverage ... 8-12, 2013, in Indianapolis, Ind. It will take ... area hotels. , With more than 7,100 presentations ... from astronomy to zoology ― the meeting will ... assortment of spot news and feature possibilities. The ...
(Date:5/21/2013)... the path of insulin action in cells in precise ... for understanding what goes wrong in diabetes. , ... David James from Sydney,s Garvan Institute of Medical Research, ... the prestigious journal Cell Metabolism . , First ... important role in the body because it helps us ...
(Date:5/20/2013)... Bacteria resistant to the antibiotic colistin are also ... human body, according to a study in ... American Society for Microbiology. Cross-resistance to colistin and ... the body against bacterial attack, could mean that ... saddled with a crippled immune response. Colistin is ...
Breaking Biology News(10 mins):Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... book designed for parents helps them better understand the ... fight them, while offering practical advice for preventing infections ... Your Kids: The Complete Guide to Protecting (without Overprotecting) ... Press, is the inside source on germ defense ...
... proteins have finally explained why computer models of proteins ... This work could have vast implications in bioengineering and ... between structure and function in these basic building blocks ... as the cover article of the Oct. 16 issue ...
... average price for all types of gasoline is holding ... at the pump might be short-lived as research from ... biggest hurdles to the wide-scale production of fuel cell-powered ... biomolecular engineering, led the research team in discovering a ...
Cached Biology News:Handbook helps parents deal with childhood infections 2Speed plays crucial role in breaking protein's H-bonds 2Speed plays crucial role in breaking protein's H-bonds 3Fuel cells gearing up to power auto industry 2Fuel cells gearing up to power auto industry 3
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known virus microRNAs ...
...
... is an excellent choice for supporting hydrocarbon processing. ... GC, this one-channel workhorse can double sample throughput ... one. You get all the capability and reliability ... instrument that has the same proven performance of ...
... GC-8A is Shimadzu's basic gas chromatograph model ... use, the GC-8A supports a single detector, ... injection port(s), and analog output. Isothermal or ... The GC-8A is only 17.3 inches (43.9 ...
Biology Products: